ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
7,890.10
-0.91%
S&P ASX All Technology
3,489.20
-4.01%
Brent Oil
69.385
0.50%
US Dollar vs AUD
1.58753
-0.33%
Bitcoin
82,500.00
5.13%
Pepperstone
Advertisement
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. IGM Biosciences Inc (IGMS) Share Price

IGM Biosciences Inc

IGM Biosciences Inc (IGMS)

NASDAQ
1.3405
0.0005
( 0.04% )
Updated: 05:21:02
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
1.3405
Bid
1.34
Offer
1.35
Volume
98,818
1.29 Day's Range 1.35
1.1874 52 Week Range 22.50
Market Cap
79.712M
Previous Close
1.34
Open
1.3001
Last Trade
1
@
1.3413
Last Trade Time
05:21:59
Financial Volume
US$ 129,801
VWAP
1.3135
Average Volume (3m)
491,071
Shares Outstanding
59,464,181
Dividend Yield
-
PE Ratio
-0.31
Earnings Per Share (EPS)
-4.14
Revenue
2.13M
Net Profit
-246.42M

About IGM Biosciences Inc

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking ago... IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.igmbio.com
Headquarters
Dover, Delaware, USA
Founded
-
IGM Biosciences Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IGMS. The last closing price for IGM Biosciences was US$1.34. Over the last year, IGM Biosciences shares have traded in a share price range of US$ 1.1874 to US$ 22.50.

IGM Biosciences currently has 59,464,181 shares in issue. The market capitalisation of IGM Biosciences is US$79.68 million. IGM Biosciences has a price to earnings ratio (PE ratio) of -0.31.

Ask ADVFN Intelligence (AI)

IGMS Latest News

More News

Form 8-K/A - Current report: [Amend]
Edgar (US Regulatory)
07 March 2025
IGMS (0.04%)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Edgar (US Regulatory)
07 March 2025
IGMS (0.04%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
18 January 2025
IGMS (0.04%)

Form 8-K - Current report
Edgar (US Regulatory)
11 January 2025
IGMS (0.04%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
04 January 2025
IGMS (0.04%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
04 January 2025
IGMS (0.04%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
04 January 2025
IGMS (0.04%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
03 January 2025
IGMS (0.04%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
19 December 2024
IGMS (0.04%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.11058.98373983741.231.4251.18742494551.34533874CS
4-0.0295-2.153284671531.371.551.18742374331.36710993CS
12-6.2628-82.36949745517.60337.661.18744910712.38986183CS
26-9.9395-88.116134751811.2822.51.18743859087.5060731CS
52-11.2595-89.361111111112.622.51.18743413558.34347755CS
156-16.0195-92.278225806517.3635.981.187436813915.15380419CS
260-47.7995-97.272079772149.141331.187429800027.52794858CS

IGMS - Frequently Asked Questions (FAQ)

What is the current IGM Biosciences share price?
The current share price of IGM Biosciences is US$ 1.3405
How many IGM Biosciences shares are in issue?
IGM Biosciences has 59,464,181 shares in issue
What is the market cap of IGM Biosciences?
The market capitalisation of IGM Biosciences is USD 79.68M
What is the 1 year trading range for IGM Biosciences share price?
IGM Biosciences has traded in the range of US$ 1.1874 to US$ 22.50 during the past year
What is the PE ratio of IGM Biosciences?
The price to earnings ratio of IGM Biosciences is -0.31
What is the cash to sales ratio of IGM Biosciences?
The cash to sales ratio of IGM Biosciences is 36.31
What is the reporting currency for IGM Biosciences?
IGM Biosciences reports financial results in USD
What is the latest annual turnover for IGM Biosciences?
The latest annual turnover of IGM Biosciences is USD 2.13M
What is the latest annual profit for IGM Biosciences?
The latest annual profit of IGM Biosciences is USD -246.42M
What is the registered address of IGM Biosciences?
The registered address for IGM Biosciences is CORPORATION TRUST CENTER, 1209 ORANGE ST, DOVER, DELAWARE, 19901
What is the IGM Biosciences website address?
The website address for IGM Biosciences is www.igmbio.com
Which industry sector does IGM Biosciences operate in?
IGM Biosciences operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RAYRaytech Holding Ltd
US$ 1.95
(124.14%)
89.5M
SYRSSyros Pharmaceuticals Inc
US$ 0.1658
(81.00%)
649.84M
TSVT2seventy bio Inc
US$ 4.945
(76.61%)
28.77M
HSAIHesai Group
US$ 23.60
(47.41%)
22.3M
TNONTenon Medical Inc
US$ 1.805
(44.40%)
31.59M
WCTWellchange Holdings Company Limited
US$ 0.69
(-72.51%)
28.83M
ARVNArvinas Inc
US$ 8.4555
(-51.85%)
13.56M
LZMHLZ Technology Holdings Ltd
US$ 9.2141
(-41.16%)
487.33k
SPGCSacks Parente Golf Inc
US$ 0.10395
(-35.07%)
31.74M
KBSXFST Corporation
US$ 3.84
(-27.55%)
49.47k
SYRSSyros Pharmaceuticals Inc
US$ 0.1659
(81.11%)
656.69M
BHATBlue Hat Interactive Entertainment Technology
US$ 0.0394
(17.61%)
386.14M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 8.08
(9.49%)
250.68M
NVDANVIDIA Corporation
US$ 110.14
(2.95%)
248.12M
CUTRCutera Inc
US$ 0.109
(-15.18%)
209.36M

IGMS Discussion

View Posts
Monksdream Monksdream 8 months ago
IGMS under $10
👍️0
Monksdream Monksdream 10 months ago
IGMS under $10
👍️0
crudeoil24 crudeoil24 3 years ago
Truist Reiterates Buy Rating, $80 Price Target.
👍️0
crudeoil24 crudeoil24 3 years ago
Let's see if IGMS gets FDA phase I,II,III, approvals . Sanofi believes it'll happen.
👍️0
crudeoil24 crudeoil24 3 years ago
14M float!
👍️0
crudeoil24 crudeoil24 3 years ago
Tons of cash going forward > IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell $200.0 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, non-voting common stock, in an underwritten public offering. In addition, IGM intends to grant the underwriters a 30-day option to purchase up to an additional $30.0 million of shares at the public offering price, less underwriting discounts and commissions. All of the securities offered in the offering will be sold by IGM. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
J.P. Morgan, BofA Securities, Stifel, and Guggenheim Securities are acting as joint book-running managers for the offering.
👍️0
TheFinalCD TheFinalCD 3 years ago
https://ih.advfn.com/stock-market/NASDAQ/igm-biosciences-IGMS/stock-news/87682546/igm-announces-proposed-public-offering

https://www.wsgr.com/print/v2/content/185066/Firm-Advises-IGM-Biosciences%2C-Inc.-on-%24230-Million-Public-Offering.pdf
👍️0

Your Recent History

NASDAQ
IGMS
IGM Biosciences
DOWI
DWCAD
DJ Canada Total Stock Ma...
BOV
P2OD34
Insulet
NYSE
EPD
Enterprise Products Part...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads